Biocon Biologics gets Japan approval for Pegfilgrastim biosimilar
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon Biologics, a wholly owned subsidiary of Biocon, received marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, a generic version of Amgen's Neulasta. The product is developed and manufactured by Biocon Biologics, with Sandoz K.K. holding exclusive rights to promote, sell, and distribute it in Japan. This strengthens Biocon's biosimilar portfolio in Japan and supports its goal of expanding patient access to affordable medicines globally.
Positive: expands biosimilar presence in Japan market and opens revenue channel through Sandoz distribution partnership.